Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study

被引：9

作者：

Sugimoto, Rie ^{[1
]}

Satoh, Takeaki ^{[2
]}

Ueda, Akihiro ^{[3
]}

Senju, Takeshi ^{[1
]}

Tanaka, Yuki ^{[1
]}

Yamashita, Shinsaku ^{[2
]}

Koyanagi, Toshimasa ^{[3
]}

Kurashige, Tomoyuki ^{[2
]}

Higuchi, Nobito ^{[3
]}

Nakamura, Tsukasa ^{[3
]}

Tanaka, Masatake ^{[4
]}

Azuma, Yuuki ^{[4
]}

Ohno, Akari ^{[4
]}

Ooho, Aritsune ^{[5
]}

Ooe, Mari ^{[5
]}

Mutsuki, Taiji ^{[6
]}

Uchimura, Koutarou ^{[7
]}

Kuniyoshi, Masami ^{[8
]}

Tada, Seiya ^{[9
]}

Aratake, Yoshifusa ^{[9
]}

Yoshimoto, Tsuyoshi ^{[9
]}

Yamashita, Naoki ^{[9
]}

Harada, Shigeru ^{[10
]}

Nakamuta, Makoto ^{[9
]}

Motomura, Kenta ^{[11
]}

Kohjima, Motoyuki ^{[4
]}

机构：

[1] Natl Hosp Org Kyushu Canc Ctr, Dept HepatoBiliary Pancreatobgy, Fukuoka, Fukuoka, Japan

[2] Kokura Med Ctr, Dept Ctr Liver Disuse, Kitakyushu, Fukuoka, Japan

[3] Fukuoka City Hosp, Dept Internal Med, Fukuoka, Fukuoka, Japan

[4] Kyushu Univ, Dept Med & Bioregulatory Sci, Grad Sch Med Sci, Fukuoka, Fukuoka, Japan

[5] Steel Mem Yawata Hosp, Dept Hepatoiocgy, Kitakyushu, Fukuoka, Japan

[6] Social & Nuance Nakabaru Hosp, Kasuya, Fukuoka, Japan

[7] Kyushu Rosai Hosp, Dept Gastroenterol, Kitakyushu, Fukuoka, Japan

[8] Fukuokahigashi Med Ctr, Dept Gastroenterol & Hepatol, Koga, Fukuoka, Japan

[9] Natl Hosp Org Kyushu Med Ctr, Dept Gastroenterol, Fukuoka, Fukuoka, Japan

[10] Chihaya Hosp, Dept Gastroenterol, Fukuoka, Japan

[11] Aso Iizuka Hosp, Dept Hepatol, Iizuka, Fukuoka, Japan

来源：

MEDICINE | 2022年 / 101卷 / 40期

关键词：

atezolizumab plus bevacizumab; hepatocellular carcinoma; RECIST; mRECIST; MTA pretreatment; LENVATINIB; SORAFENIB; HYPERPROGRESSION; MANAGEMENT; CANCER; JAPAN; GRADE;

D O I：

10.1097/MD.0000000000030871

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To evaluate the efficacy of atezolizumab plus bevacizumab treatment in patients with hepatocellular carcinoma (HCC) previously treated with molecular targeted agents (MTAs). Thirty-one patients treated with atezolizumab plus bevacizumab for unresectable HCC and previously treated with MTAs were enrolled in this study. The treatment lines ranged from second to sixth lines. The treatment effect on HCC differed from that during first-line treatment. The treatment effect was determined using the Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST. The treatment response was different for each MTA immediately prior to atezolizumab + bevacizumab treatment. Tumors treated with lenvatinib followed by atezolizumab + bevacizumab showed rapid growth for a short period of time followed by shrinkage. However, patients who received ramucirumab, sorafenib, and regorafenib did not show such changes. This was likely because of differences in the mechanism of action of the MTA administered immediately beforehand. The side-effect profile differed from that observed in the IMbrave150 phase 3 study of atezolizumab plus bevacizumab, which showed more adverse events related to hepatic reserve. Patients treated with the combination of atezolizumab and bevacizumab after lenvatinib therapy may experience rapid tumor growth and subsequent shrinkage.

引用

页数：9

共 35 条

[1] Hyperprogression after immunotherapy [J].

Abbas, Waseem ;

Rao, Ranga Raju ;

Popli, Swati .

SOUTH ASIAN JOURNAL OF CANCER, 2019, 8 (04) :244-246

[2] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[3] Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact? [J].

Adashek, Jacob J. ;

Subbiah, Ishwaria M. ;

Matos, Ignacio ;

Garralda, Elena ;

Menta, Arjun K. ;

Ganeshan, Dhakshina Moorthy ;

Subbiah, Vivek .

TRENDS IN CANCER, 2020, 6 (03) :181-191

[4] Molecular insight of regorafenib treatment for colorectal cancer [J].

Arai, Hiroyuki ;

Battaglin, Francesca ;

Wang, Jingyuan ;

Lo, Jae Ho ;

Soni, Shivani ;

Zhang, Wu ;

Lenz, Heinz-Josef .

CANCER TREATMENT REVIEWS, 2019, 81

[5] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

[6]

Cheng AL, 2019, ANN ONCOL, V30

[7] Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma [J].

Chuma, Makoto ;

Uojima, Haruki ;

Numata, Kazushi ;

Hidaka, Hisashi ;

Toyoda, Hidenori ;

Hiraoka, Atsushi ;

Tada, Toshifumi ;

Hirose, Shunji ;

Atsukawa, Masanori ;

Itokawa, Norio ;

Arai, Taeang ;

Kako, Makoto ;

Nakazawa, Takahide ;

Wada, Naohisa ;

Iwasaki, Shuitirou ;

Miura, Yuki ;

Hishiki, Satoshi ;

Nishigori, Shuhei ;

Morimoto, Manabu ;

Hattori, Nobuhiro ;

Ogushi, Katsuaki ;

Nozaki, Akito ;

Fukuda, Hiroyuki ;

Kagawa, Tatehiro ;

Michitaka, Kojiro ;

Kumada, Takashi ;

Maeda, Shin .

CANCERS, 2020, 12 (02)

[8] Management of Antiangiogenic Therapy-Induced Hypertension [J].

de Jesus-Gonzalez, Nilka ;

Robinson, Emily ;

Moslehi, Javid ;

Humphreys, Benjamin D. .

HYPERTENSION, 2012, 60 (03) :607-615

[9] Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy [J].

Ferrara, N ;

Hillan, KJ ;

Novotny, W .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 333 (02) :328-335

[10] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].

Finn, Richard S. ;

Qin, Shukui ;

Ikeda, Masafumi ;

Galle, Peter R. ;

Ducreux, Michel ;

Kim, Tae-You ;

Kudo, Masatoshi ;

Breder, Valeriy ;

Merle, Philippe ;

Kaseb, Ahmed O. ;

Li, Daneng ;

Verret, Wendy ;

Xu, Derek-Zhen ;

Hernandez, Sairy ;

Liu, Juan ;

Huang, Chen ;

Mulla, Sohail ;

Wang, Yulei ;

Lim, Ho Yeong ;

Zhu, Andrew X. ;

Cheng, Ann-Lii .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905

← 1 2 3 4 →